Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12-01Estimated
Enrollment · participants286Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.